Australia's most trusted
source of pharma news
Wednesday, 24 April 2024
Posted 23 November 2021 PM
Undeterred by its recent PBAC rejection, Janssen is continuing to roll out its anti-depressant nasal spray Spravato across Australia.
Twenty centres across the nation, each with their own individual referral criteria, will accept adult patients with treatment resistant depression - major depression that has not responded to at least two different treatments.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.